NCT07032532View on ClinicalTrials.gov

Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Peripheral T Cell Lymphoma
Interventions
DRUG

Golidocitinib

Golidocitinib 150mg orally once daily in a 21-day cycle

DRUG

Golidocitinib plus CHOP

Golidocitinib 150mg orally every other day with CHOP (Cyclophosphamide: 750mg/m2, IV, d1 ; Doxorubicin: 50mg/m2, IV, d1; Vincristine: 1.4mg/m2, IV, d1 ; Prednison: 100mg, po, d1-5) in a 21-day cycle for 6 cycles.

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guanzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER